PharmaEssentia Reports Positive Long-Term Data for BESREMi in Essential Thrombocythemia
Event summary
- PharmaEssentia will present two-year results from the Phase 3 SURPASS-ET study at the SOHO 2026 Annual Meeting, showing sustained efficacy and safety of BESREMi in high-risk essential thrombocythemia (ET) patients.
- Real-world evidence from a retrospective cohort study of 55 ET patients indicates BESREMi's effectiveness in community oncology settings, particularly in younger patients.
- The presentations will be held on September 9, 2026, in Houston, Texas, with Dr. Lucia Masarova and Dr. Solly Chedid as presenters.
The big picture
PharmaEssentia's presentation of positive long-term data for BESREMi underscores the growing importance of targeted therapies in hematologic oncology. The real-world evidence further supports the drug's potential to address unmet needs in ET patients, particularly those resistant to or intolerant of existing treatments. As the biopharmaceutical industry continues to focus on precision medicine, PharmaEssentia's findings could enhance its competitive positioning in the hematology space.
What we're watching
- Clinical Validation
- Whether the long-term efficacy and safety data from the SURPASS-ET study will strengthen BESREMi's position in the ET treatment landscape.
- Market Expansion
- The pace at which PharmaEssentia can leverage real-world evidence to expand BESREMi's use in community oncology settings.
- Regulatory Dynamics
- How the ongoing long-term efficacy and safety analyses may impact future regulatory decisions for BESREMi.
Related topics